Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Lipid Metabolism

Background:

• Cholesteryl ester transfer protein (CETP) inhibition is explored to increase HDL cholesterol and manage residual cardiovascular risk.
• Anacetrapib targets CETP, aiming to improve lipid profiles in patients with or at high risk for coronary heart disease.

Purpose of the Study:

• To evaluate the efficacy and safety of anacetrapib in reducing LDL cholesterol and increasing HDL cholesterol.
• To assess the long-term safety and lipid-modifying effects of anacetrapib in a high-risk cardiovascular population.

Main Methods:

• The Phase III DEFINE trial involved patients with or at high risk for coronary heart disease.
• Participants received anacetrapib or placebo, with primary endpoints assessed at 24 weeks and safety through 76 weeks.

Main Results:

• Anacetrapib reduced LDL cholesterol by 39.8% and increased HDL cholesterol by 138.1% compared to placebo.
• The treatment showed an acceptable safety profile with no significant changes in blood pressure, aldosterone, or electrolytes.
• No increase in cardiovascular events was observed, unlike a previous CETP inhibitor.

Conclusions:

• Anacetrapib demonstrates significant efficacy in improving lipid profiles, lowering LDL and raising HDL cholesterol.
• The drug exhibits a favorable safety profile and sustained lipid-modifying effects, even after treatment cessation.
• Anacetrapib represents a promising therapeutic strategy for managing cardiovascular risk in specific patient populations.